Significance of rosiglitazone inhibiting TLR4 expression in partial hepatic ischemia/reperfusion of mice

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 28, Issue 5, 2008, Pages 564-567

  Zhai, Dongsheng ^a,b   Zhang, Jinxiang ^a   Zheng, Qichang ^a   Li, Zhengliang ^a   Zhang, Jinhui ^a   Tian, Yuan ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUBEI UNIVERSITY FOR NATIONALITIES   (China)

Author keywords

Hepatic reperfusion injury; Peroxisome proliferator activated receptor ; Rosiglitazone; Toll like receptor

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; LIGAND; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TLR4 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 4;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; DOWN REGULATION; DRUG EFFECT; GENETICS; LIVER; MALE; METABOLISM; MOUSE; RANDOMIZATION; REPERFUSION INJURY; VASCULARIZATION;

ANIMALS; DOWN-REGULATION; LIGANDS; LIVER; MALE; MICE; MICE, INBRED BALB C; PPAR GAMMA; RANDOM ALLOCATION; REPERFUSION INJURY; RNA, MESSENGER; THIAZOLIDINEDIONES; TOLL-LIKE RECEPTOR 4;

EID: 58449103075     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-008-0516-8     Document Type: Article

References (13)

1. F. Constantino W. B. Ronald W. K. Jerzy 2003 Hepatic ischemia/reperfusion injury-a fresh look Exp Mol Pathol 74 86
2. A. Nakajima K. Wada H. Miki 2001 Endogenous PPARγ mediates anti-inflammatory activity in murine ischemia-reperfusion injury Gastroenterology 120 460 469
3. D. K. Lawlor R. W. Brock K. A. Harrls 1999 Cytokines contribute to early hepatic parenchymal injury and microvascular dysfuntion after bilateral hind limb ischemia J Vasc Surg 30 4 533 541
4. H. Yoshidome A. Kato M. J. Edwards 1999 Interleukin-10 suppresses hepatic-ischemia reperfusion injury in mice: implications of a control role for nuclear factor kappaB Hepatology 30 2 203 208
5. O. Le Moine H. Louis A. Demols 2000 Cold liver ischemia/reperfusion injury critically depends on liver T cells and is improved by donor pretreatment with interleukin 10 in mice Hepatology 31 6 1266 1274
6. G. J. Murphy J. C. Holder 2000 PPAR-g agonists: therapeutic role in diabetes, inflammation and cancer Trends Pharmacol Sci 21 469 474
7. L. G. Pascual C. K. Glass 2000 Peroxisome proliferator-activat ed receptor gamma-dependent repression of the inducible nitric oxide synthase gene Mol Cell Biol 20 4699 4707
8. C. Jiang A. T. Ting B. Seed 1998 PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines Nature 391 82 86
9. K. Wada A. Nakajima H. Takahashi 2004 Protective effect of endogenous PPARγ against acute gastric mucosal lesions associated with ischemia-reperfusion Am J Physiol Gastrointest Liver Physiol 287 G452 G458
10. S. Cuzzocrea B. Pisano L. Dugo 2003 Rosiglitazone and 5-deoxy-delta12, 14-preostaglandinJ2, ligand of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischemia/reperfusion injury of the gut Br J Pharmacol 140 366 376
11. K. Takeda T. Kaisho S. Akira 2003 Toll-like receptors Annu Rev Immunol 21 335 376
12. Y. Zhai X. D. Shen R. O'Connell 2004 Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent Pathway J Immunol 173 7115 7119
13. S. Appel V. Mirakaj A. Bringmann 2005 PPAR-γ agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-κB pathways Blood 106 3888 3894